<DOC>
	<DOC>NCT02639338</DOC>
	<brief_summary>This study will evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 8 weeks and of treatment with sofosbuvir/velpatasvir (SOF/VEL) FDC for 12 weeks in adults with chronic genotype 3 hepatitis C virus (HCV) infection and cirrhosis who have not previously received treatment with direct-acting antiviral (DAA) therapy.</brief_summary>
	<brief_title>Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Willing and able to provide written informed consent HCV RNA ≥ 10^4 IU/mL at screening Chronic genotype 3 HCV infection (≥ 6 months) Presence of cirrhosis HCV treatment naive or treatment experienced with an interferon (IFN)based regimen Use of protocol specified methods of contraception Key Current or prior history of clinically significant illness that may interfere with participation in the study Screening ECG with clinically significant abnormalities Laboratory parameters outside the acceptable range at screening Pregnant or nursing female Chronic liver disease not caused by HCV Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic</keyword>
</DOC>